U2OS-Cas9 and U2OS-Cas9-NLS cell line generation

JW Jack T. Whelan
RS Ragunath Singaravelu
FW Fuan Wang
AP Adrian Pelin
LT Levi A. Tamming
GP Giuseppe Pugliese
NM Nikolas T. Martin
MC Mathieu J. F. Crupi
JP Julia Petryk
BA Bradley Austin
XH Xiaohong He
RM Ricardo Marius
JD Jessie Duong
CJ Carter Jones
EF Emily E. F. Fekete
NA Nouf Alluqmani
AC Andrew Chen
SB Stephen Boulton
MH Michael S. Huh
MT Matt Y. Tang
ZT Zaid Taha
ES Elena Scut
JD Jean-Simon Diallo
TA Taha Azad
BL Brian D. Lichty
CI Carolina S. Ilkow
JB John C. Bell
request Request a Protocol
ask Ask a question
Favorite

Lentivector expressing Cas9 without nuclear localization sequence was generated by subcloning Cas9 without NLS from lenti-Cas9-blast (26), using primers described in Supplementary Table 1 , into pLenti CMV/TO Puro (27). Restriction cloning was performed using BamHI/XbaI restriction enzymes. Lentivirus was generated by transfecting use Lenti-X 293T cell line (Takarabio) by transfecting cells with pCMV-TO Puro-Cas9 or pLenti-Cas9-Blast (contains NLS), pSPAX2, and pMD.2 (3:2:1 ratio) using Lipofectamine 2000 (2 µL/1ug DNA). Supernatants were collected approximately 48 and 72h hours after transfection and passed through a 0.45-μm filter and added to cells. Appropriate antibiotic cell selection was performed to isolate stably transduced cell lines. Clonal selection of U2OS-Cas9 cells was performed by limiting dilution and immunoblot analyses was performed to identify clones with the highest level of Cas9 expression (refer to Supplementary Figure 1 ). U2OS-Cas9 cells were maintained under puromycin selection (1 μg/mL).

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A